ELTX
Elicio Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.68
close · 2026-10-30
value
2
cheaper than peers2
quality
5
stronger fundamentals5
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 4.64× | 32 |
| earnings yield, 3 years ago | -160.5% | 26 |
| cash flow yield, 3 years ago | -50.2% | 21 |
| cash flow yield, 2 years ago | -72.0% | 17 |
| cash flow yield, 1 year ago | -81.6% | 16 |
| cash flow yield, latest year | -81.2% | 13 |
| earnings yield, latest year | -153.6% | 11 |
| earnings yield, 2 years ago | -414.3% | 8 |
| earnings yield, 1 year ago | -253.0% | 7 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 178.3% | 4 |
| return on equity | -774.6% | 2 |
3 of 4 measures available
Facts
| market cap | $46M |
| free cash flow | -$22.3M |
| employees | 33 |
| first trade | 2021-02-05 |
| next earnings | not reported |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.58 | -4.25 | -6.96 | -2.70 |
| free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M |
| net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | -$1.9M | -$3.7M | $1.2M | -$943,000 |